News

A novel combination therapy shows promise for advanced lung cancer patients resistant to standard treatments, offering hope for improved survival rates.

Suresh S. Ramalingam, MD, FACP, FASCO, emphasizes the role of community oncologists in translating new advancements in lung cancer research into widespread patient benefit.

LB2102 showed early antitumor activity and no DLTs in small cell lung cancer and large cell neuroendocrine carcinoma.

Abhishek Maiti, MD, discussed the EVICTION trial in AML and results presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple myeloma.

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a positive trend in overall survival.

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a manageable safety profile.

Higher pretreatment HER2 amplicon mRNA and HER2 protein levels predicted improved time to next treatment with T-DXd in metastatic breast cancer. Conversely, higher TOPO1 protein correlated with worse outcomes.

Adding cobolimab to dostarlimab as neoadjuvant treatment for high-risk resectable melanoma improved major pathological response rates and was tolerable.

Undetectable ctDNA at cycle 6 strongly predicts reduced progression/death risk in locally advanced cervical cancer patients treated with durvalumab/CRT or CRT alone.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

A single cilta-cel infusion led to 33% of heavily pretreated relapsed/refractory multiple myeloma patients remaining progression-free at 5+ years.

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.

Fruquintinib with chemotherapy and PD-1 blockade showed promising efficacy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.

Ziftomenib shows promising results in treating relapsed/refractory NPM1-mutant AML, achieving significant remission rates and a favorable safety profile.

Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.

Vincent Picozzi, MD, discusses findings from the phase 3 trial PANOVA-3 of TTFields with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.

The ShorTrip trial found that short-course radiotherapy followed by FOLFOX and FOLFOXIRI improved pathological response rates in locally advanced rectal cancer.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.

Lifileucel therapy shows promising long-term survival and response rates in advanced melanoma patients, offering hope for those with limited treatment options.

Olaparib and radium-223 bested radium-223 alone in radiographic progression-free survival in men with castration-resistant prostate cancer.

Darolutamide is now an FDA-approved treatment option alone or in combination with docetaxel for metastatic castration-sensitive prostate cancer.